Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

1037055

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to meet the target for every person affected by cancer to have access to a recovery package by 2020.
tabling member constituency	Hove
tabling member printed	Peter Kyle
uin	205985
answer	answer is ministerial correction date of answer 10/01/2019 answer text <p>Cancer Alliances across England have been funded to introduce recovery package interventions starting in April 2017. Significant progress is being made and currently nearly every National Health Service trust has at least one cancer team providing the key components of the recovery package. As described in the new NHS Long Term Plan, by 2021, every person diagnosed with cancer will have access, where appropriate, to personalised care, including needs assessment, a care plan and health and wellbeing information and support. This will be delivered in line with the NHS Comprehensive Model for Personalised Care. This will empower people to manage their care and the impact of their cancer, and maximise the potential of digital and community-based support. Over the next three years every patient with cancer will get a full assessment of their needs, an individual care plan and information and support for their wider health and wellbeing.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/01/2019 17:15:59 answering member 4067 label Biography information for Steve Brine
tabling member	4505 label Biography information for Peter Kyle

1037068

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of patients who have been (a) prescribed medicinal cannabis through the NHS and (b) denied a prescription for medicinal cannabis through the NHS since its use was legalised in November 2018.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	205815
answer	answer is ministerial correction date of answer 10/01/2019 answer text <p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.</p><p> </p><p>The Department does not hold information on the number of patients denied access to prescriptions for medicinal cannabis.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/01/2019 17:08:42 answering member 4067 label Biography information for Steve Brine
tabling member	308 label Biography information for Mr Jim Cunningham

1037183

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has plans to renegotiate the community pharmacy contractual framework; and if he will make a statement.
tabling member constituency	Darlington
tabling member printed	Jenny Chapman
uin	205887
answer	answer is ministerial correction date of answer 10/01/2019 answer text <p>The Department will be seeking to renegotiate the Community Pharmacy Contractual Framework. Community pharmacies play a vital role within our health and care system and the Department remains committed to working closely with the Pharmaceutical Services Negotiating Committee to better utilise the reach and skill set of pharmacy teams.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/01/2019 17:17:09 answering member 4067 label Biography information for Steve Brine
tabling member	3972 label Biography information for Baroness Chapman of Darlington

1037185

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with the Cabinet Office on potential reforms to the community pharmacy sector.
tabling member constituency	Darlington
tabling member printed	Jenny Chapman
uin	205888
answer	answer is ministerial correction date of answer 10/01/2019 answer text <p>As is customary, the Department regularly engages the Cabinet Office across a wide range of policy issues. Ongoing discussions continue between the Department and the Cabinet Office on the role of community pharmacy and the important contribution of pharmacy teams as outlined in the NHS Long Term Plan.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/01/2019 17:18:08 answering member 4067 label Biography information for Steve Brine
tabling member	3972 label Biography information for Baroness Chapman of Darlington

1037187

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 October 2018 to Question 181567, what the average fee per prescription item is including the retained medicine margin for (a) a pharmacy which dispensed an average mean number of prescription items in 2017-18, (b) a pharmacy which dispensed the highest number of prescription items in 2017-18, (c) a pharmacy which dispensed the lowest number of prescription items in 2017-18 and (d) a pharmacy which is in the bottom quartile of all pharmacies for the number of prescription items it dispensed in 2017-18.
tabling member constituency	Darlington
tabling member printed	Jenny Chapman
uin	205889
answer	answer is ministerial correction date of answer 10/01/2019 answer text <p>The following table shows the average fee relating to essential services per prescription item for pharmacies with different levels of dispensing activity for the period 2017/18 and also includes medicine margin.</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Average fee per prescription item including margin</p></td></tr><tr><td><p>Pharmacy with mean number of prescription items</p></td><td><p>£2.37</p></td></tr><tr><td><p>Pharmacy with highest number of prescription items</p></td><td><p>£2.10</p></td></tr><tr><td><p>Pharmacy with lowest number of prescription items</p></td><td><p>£2.07</p></td></tr><tr><td><p>Pharmacy with lowest quartile number of prescription items</p></td><td><p>£2.57</p></td></tr></tbody></table><p> </p><p>We have calculated total fees as the sum of all essential service fees, including establishment payments and quality payments. It excludes any advanced service fees as these are payments for activity not related to dispensing. Any funding received via retained medicine margin, and any payments relating to the Pharmacy Access Scheme have similarly been excluded from this analysis and so would need to be separately considered.</p><p> </p><p>The medicine margin retained by individual pharmacy contractors is not known, therefore it can only be calculated by using the number of pharmacy contractors and the total medicine margin as per the Community Pharmacy Contractual Framework (which in 2017/18 was £800 million).</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/01/2019 17:01:26 answering member 4067 label Biography information for Steve Brine
tabling member	3972 label Biography information for Baroness Chapman of Darlington

1037188

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 October 2018 to Question 181567, to list (a) the distance selling pharmacies used in the calculation provided in that Answer, (b) the average number of items dispensed each month for each in 2017/18 and (c) the average fee earned per prescription item for each in 2017-18.
tabling member constituency	Darlington
tabling member printed	Jenny Chapman
uin	205890
answer	answer is ministerial correction date of answer 10/01/2019 answer text <p>The list of distance selling pharmacies used in that calculation is in the attached table alongside their average number of prescription items in 2017/18. It would prejudice companies’ commercial interest to disclose the average fee per prescription item for each individual contractor and for this reason this information is provided as a range between £1.25 and £23.74.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/01/2019 17:05:04 answering member 4067 label Biography information for Steve Brine attachment 1 file name PQ205890 table.docx title PQ205890 attached table
tabling member	3972 label Biography information for Baroness Chapman of Darlington

1037190

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to page 82 of the NHS Long Term Plan, what specific reforms to reimbursement and supply arrangements for community pharmacy his Department is considering.
tabling member constituency	Darlington
tabling member printed	Jenny Chapman
uin	205891
answer	answer is ministerial correction date of answer 10/01/2019 answer text <p>As outlined in the published final package of, ‘Community Pharmacy in 2016/17 and beyond’<sup>1</sup>, the Government is committed to pursuing a number of reimbursement reforms and taking steps to improve the prescription ordering journey to maximise patient choice and convenience.</p><p> </p><p>The reimbursement reforms include:</p><p>- ‘non Part VIII’ products, i.e. products with no reimbursement price listed in Part VIII of the Drug Tariff;</p><p>- changes to Category M for certain generic medicines to better reflect their market price;</p><p>- changes to the margin survey to account for multiple suppliers for Non Part VIII products and Category C products;</p><p>- ‘splitting the discount’- to reflect that in general generic medicines have increased margin over brands; and</p><p>- changes to the way Category A prices are set.</p><p>The Government has also recently committed to reforming reimbursement arrangements for specials.</p><p> </p><p>Note:</p><p><sup>1</sup><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/561495/Community_pharmacy_package_A.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/561495/Community_pharmacy_package_A.pdf</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/01/2019 17:06:57 answering member 4067 label Biography information for Steve Brine
tabling member	3972 label Biography information for Baroness Chapman of Darlington

1037196

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress has been made in negotiations between NHS England and Vertex on the supply of Orkambi to treat people with cystic fibrosis.
tabling member constituency	Wigan
tabling member printed	Lisa Nandy
uin	205913
answer	answer is ministerial correction date of answer 10/01/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) and NHS England are leading the dialogue with Vertex Pharmaceuticals around access to their portfolio of cystic fibrosis medicines. It is critical that Vertex now re-engages fully with the NICE appraisal process and gives serious consideration to the portfolio deal offer that NHS England made at the end of July. This deal would provide immediate access for patients to all Vertex licensed medicines and future pipeline products once licensed and in advance of the individual NICE appraisals concluding. The Government fully supports the approach that NICE and NHS England are adopting. It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS and would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are encouraged that there is continued dialogue between all parties.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/01/2019 17:10:14 answering member 4067 label Biography information for Steve Brine
tabling member	4082 label Biography information for Lisa Nandy

1037238

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the potential merits of the recommendations contained in the Independent Breast Screening Review will be included in the review of breast screening by the National Screening Committee.
tabling member constituency	Halton
tabling member printed	Derek Twigg
uin	205825
answer	answer is ministerial correction date of answer 10/01/2019 answer text <p>The United Kingdom National Screening Committee (UK NSC) welcomes the Independent Breast Screening Review report 2018 and will review the recommendations set out.</p><p> </p><p>In the meantime, the evidence to routinely screen women over 70 years of age is limited and we await the results of the Age Extension trial to help provide essential evidence needed to help better understand what the benefit and harms are when offering screening in women aged 71 to 73. The UK NSC is also looking at the age at which screening should no longer be routinely offered.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/01/2019 17:14:31 answering member 4067 label Biography information for Steve Brine
tabling member	429 label Biography information for Derek Twigg

1035112

registered interest
date	04/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the implications for his policies of the report entitled, Global Action Plan for the Prevention and Control of NCDs 2013-2020, published by the World Health Organisation; and if he will make statement.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	205213
answer	answer is ministerial correction date of answer 09/01/2019 answer text <p>The Government supports the World Health Organization’s (WHO) ‘Global Action Plan for the Prevention and Control of NCDs 2013-2020’ and has implemented a range of policies which contribute to reducing and controlling non-communicable diseases (NCDs). These include policies to reduce smoking; promote healthy diets; tackle misuse of alcohol; and encourage physical exercise. All of these policies are well-aligned with the WHO’s recommended actions on NCDs.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/01/2019 15:14:44 answering member 4067 label Biography information for Steve Brine
tabling member	1453 label Biography information for Andrew Selous